Zimmer Biomet (ZBH) to Release Earnings on Monday

Zimmer Biomet (NYSE:ZBH) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of $1.77 per share and revenue of $1.89 billion for the quarter. Zimmer Biomet has set its FY 2025 guidance at 8.150-8.350 EPS.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the firm posted $2.20 earnings per share. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $102.08 on Friday. The firm has a 50 day moving average of $105.53 and a 200 day moving average of $106.51. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $20.20 billion, a price-to-earnings ratio of 22.94, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. Zimmer Biomet has a 52 week low of $93.10 and a 52 week high of $122.25.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.94%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet’s payout ratio is 21.57%.

Analyst Ratings Changes

A number of brokerages have commented on ZBH. Royal Bank of Canada reduced their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Raymond James decreased their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. JMP Securities reiterated a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Truist Financial restated a “hold” rating and set a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Finally, Stifel Nicolaus raised their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $124.15.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.95% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Zimmer Biomet stock. Brighton Jones LLC purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,936 shares of the medical equipment provider’s stock, valued at approximately $204,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.